Gene Editing Startup Beam Therapeutics Launches With $87M in Series A Funds

May 17, 2018

|

NEW YORK (GenomeWeb) – Beam Therapeutics announced today that it has launched with $87 million in Series A funding to develop precision genetic medicines that make edits to individual base pairs in the genome.

The funding round was led by F-Prime Capital Partners and ARCH Venture Partners.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Breaking News

The Scan

Not Quite There Yet

According to CNBC, Pfizer has announced that its SARS-CoV-2 vaccine data won't be ready this week.

Call for Open Science

A number of United Nations agencies push for scientific findings to be made accessible through open science.

Accolades for a New University

Paris-Saclay University garners international regard following a decade-long effort to establish the new research university, Nature News reports.

Nucleic Acids Research Papers on IndiGenomes, DockCoV2, ViruSurf Databases

In Nucleic Acids Research this week: database to house IndiGen sequencing data, database of SARS-CoV-2 docking scores, and more.

Menu

Gene Editing Startup Beam Therapeutics Launches With $87M in Series A Funds

To read the full story....

Breaking News

Biocartis, Exact Sciences Discussing Potential Termination of Oncotype DX Agreement

Maverick Therapeutics to Use Inivata's Liquid Biopsy Assay in Phase I/II Clinical Study

Angle H1 Revenues Drop 39 Percent on Coronavirus Impact

Inflammatix Awarded $7.4M in Additional BARDA Funding for POC System, Acute Infection Test

PerkinElmer Q3 Revenues Spike 36 Percent

GenMark Q3 Revenues More Than Double on Respiratory Panel Sales

The Scan

Not Quite There Yet

Call for Open Science

Accolades for a New University

Nucleic Acids Research Papers on IndiGenomes, DockCoV2, ViruSurf Databases

What's Popular?

Biodesix Prices $72M IPO

Agena Bioscience Gets FDA Emergency Use Authorization for MassArray Coronavirus Test

Exact Sciences Aiming to Make Pan-Cancer Blood Screening Part of Standard Medical Care

Qiagen Reports 26 Percent Q3 Revenue Growth; Ups Full-Year Guidance

Exact Sciences to Acquire Thrive Earlier Detection for up to $2.15B; Q3 Revenues Spike 87 Percent

Sponsorships